Nebivolol is a novel beta1-blocker with a greater degree of selectivity for beta1-adrenergic
receptors than other agents in this class and a nitric oxide (NO)-potentiating, vasodilatory …

In various embodiments, the present disclosure provides methods reducing the risk of
cardiovascular events in a subject on statin therapy by administering to the subject a …

Background Clinical studies indicate that vitamin D3 improves circulation and may have
beneficial effects in hypertension. This study uses nanomedical systems to investigate the …

Nebivolol is a β-blocker under US Food and Drug Administration review for the treatment of
hypertension. The unique pharmacologic properties of nebivolol include high specificity for …

Asymmetric dimethylarginine (ADMA) is a competitive endogenous inhibitor of nitric oxide
synthase with a key role in the pathophysiology of endothelial dysfunction, in the …

Hypertensive African Americans often respond poorly to β‐blocker monotherapy, compared
with whites. There is evidence, however, that suggests that this response may be different if …

Background Free radical-mediated oxidative stress has been implicated in the
etiopathogenesis of several disorders. The aim of this study was to elucidate the effect of …

Increasing knowledge of the role of nitric oxide (NO) in physiology and disease has
stimulated efforts to target the NO pathway pharmacologically. These therapeutic strategies …

Hypertensive treatment with beta‐adrenoceptor antagonists (BAA s) has been successfully
applied for four decades. These drugs have a beneficial effect on the health of the patients …

Nebivolol is a third generation β-blocker. It is highly selective for the β1-adrenoceptor, and
has additional nitric oxide-mediated vasodilating and antioxidant properties, along with a …